Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from ALS ( (AU:ALQ) ) is now available.
ALS Limited reported a solid financial performance for FY25, with a 16% increase in underlying revenue to $3 billion, driven by strong growth in Life Sciences and a resilient Commodities sector. Despite a slight decline in underlying NPAT due to adverse foreign exchange impacts and higher interest costs, the company announced a $350 million equity raising to fund future growth initiatives. The company’s strategic acquisitions are performing well, and the transformation program for Nuvisan is ahead of schedule. ALS’s strong balance sheet supports its growth agenda, and the company remains committed to maximizing shareholder returns through its value creation framework.
The most recent analyst rating on (AU:ALQ) stock is a Buy with a A$15.20 price target. To see the full list of analyst forecasts on ALS stock, see the AU:ALQ Stock Forecast page.
More about ALS
ALS Limited operates in the Life Sciences and Commodities sectors, providing laboratory testing services with a focus on environmental, food, pharmaceutical, and industrial materials testing. The company is known for its strong market presence in these areas, leveraging a diversified revenue mix and a robust operating model to maintain resilience in fluctuating market conditions.
YTD Price Performance: 17.31%
Average Trading Volume: 1,181,483
Technical Sentiment Signal: Buy
Current Market Cap: A$8.58B
Learn more about ALQ stock on TipRanks’ Stock Analysis page.